Clinical trials: Sunitinib
Melanoma
A Phase I/II Study of Sunitinib and Dacarbazine
This is a combination Phase I/II design that explores the toxicity and activity of Sunitinib and Dacarbazine (DTIC) for metastatic melanoma.
- Trial name
- NCT00496223
- Testing
- Sunitinib, Dacarbazine
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Gastrointestinal Stromal Tumors
Sorafenib for Imatinib/Sunitinib-failed GIST
With discovery of KIT (CD117) mutations and the advent of KIT tyrosine kinase inhibitor imatinib, there has been substantial improvement in overall survival in patients with advanced and/or metastatic gastrointestinal tumors…
- Trial name
- NCT01091207
- Testing
- Sorafenib
- Where
- South Korea
- Volunteers
- 39 people
- Sponsor
- Samsung Medical Center
Cancer
Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib in Cancer Patients
Sunitinib is an anticancer drug, but like most drugs, the effect varies from person to person. This is partly due to a variation in how well each person eradicates the drug from the body.
- Trial name
- CLEARSUN (NCT01098903)
- Where
- 3 sites in Australia, Netherlands
- Volunteers
- 52 people
- Sponsor
- Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme
This clinical trial is studying how well giving cilengitide together with sunitinib malate works in treating patients with advanced solid tumors or glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Adult Solid Neoplasm
- Trial name
- NCT01122888
- Testing
- Cilengitide, Clinical Observation, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Cancer Institute (NCI)
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington
Metastatic Cancer
N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy
The metastatic lesions may be very different from the primary tumor because of intrinsic tumor heterogenity, clonal selection through metastatic process and following previous cytotoxic treatments.
- Trial name
- MetAction (NCT02142036)
- Testing
- EMA-approved ATI based targeted therapy
- Where
- 2 sites in Norway
- Volunteers
- 50 people
- Sponsor
- Oslo University Hospital
Metastatic Renal Cell Carcinoma
Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma
To evaluate the efficacy and safety of sunitinib in non-clear cell type renal cell carcinoma with the exception of pure sarcomatoid carcinoma and collecting duct carcinoma
- Trial name
- NCT01219751
- Testing
- Sunitinib
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Asan Medical Center
Gastrointestinal Neoplasms
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
The purpose of this study is to find out if a new drug, called IDRX-42 (also known as GSK6042981), is effective in treating adults with a type of cancer called Gastrointestinal Stromal Tumors (GIST) when compared to another drug…
- Trial name
- NCT07218926
- Testing
- IDRX-42, Sunitinib
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 450 people
- Sponsor
- GlaxoSmithKline
Metastatic Clear Cell Renal Cell Carcinoma
Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma
The purpose of this study is to validate of a predictive nomogram of response or resistance to targeted therapies in metastatic clear cell renal cell carcinoma
- Trial name
- RTKI (NCT02848768)
- Testing
- Sunitinib
- Where
- France
- Volunteers
- 45 people
- Sponsor
- Rennes University Hospital
Non GIST Sarcomas
Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy
The purpose of this study is to determine the safety of continuous dosing of sunitinib in association with radiotherapy in patients with non GIST (gastro intestinal stromal tumor) sarcomas who cannot be treated by surgery.
- Trial name
- NCT01308034
- Testing
- sunitinib
- Where
- 6 sites in France
- Volunteers
- 25 people
- Sponsor
- Centre Leon Berard
Renal Cell Carcinoma, Kidney Cancer
Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial
Advanced renal cell carcinoma is invariably fatal, with a life expectancy of 2-3 years since diagnosis. Sunitinib is the standard first-line treatment for this condition, but it is associated to multiple side effects, with…
- Trial name
- QUASAR (NCT02446795)
- Testing
- Sunitinib, Isoquercetin
- Where
- 5 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Consorzio Oncotech
Clear Cell Renal Cell Carcinoma, Metastasis
Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to see whether neoadjuvant administration of Sunitinib reduces the size of the primary kidney tumor in patients with metastatic disease undergoing cytoreductive surgery.
- Trial name
- NCT01069770
- Testing
- Sunitinib
- Where
- 3 sites in South Korea
- Volunteers
- 32 people
- Sponsor
- Korean Urological Oncology Society
Prostatic Neoplasms
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy
This study will compare the safety and efficacy of sunitinib in combination with prednisone versus placebo and prednisone in patients that have metastatic castration-resistant prostate cancer that has progressed after treatment…
- Trial name
- SUN 1120 (NCT00676650)
- Testing
- Prednisone, sunitinib
- Where
- 205 sites in United States, Australia and 20 more
- Volunteers
- 873 people
- Sponsor
- Pfizer
Advanced Solid Tumors
To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib.
The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of AMG 386 when used in combination with AMG 706, bevacizumab, sorafenib, or sunitinib and that at least one dose level from each combination…
- Trial name
- NCT00861419
- Testing
- Sorafenib, AMG 706, AMG 386
- Volunteers
- 88 people
- Sponsor
- Amgen
Breast Neoplasms
Open Label Study Of SU011248 In Combination With Trastuzumab For Patients With Metastatic Breast Cancer
The current study is to evaluate: Overall response rate for the combination of trastuzumab and SU011248 in metastatic or locally recurrent breast cancer; evaluate safety and tolerability of the combination; measure duration of…
- Trial name
- NCT00243503
- Testing
- SU011248/Trastuzumab
- Where
- 27 sites in United States, Belgium and 3 more
- Volunteers
- 60 people
- Sponsor
- Pfizer
Renal Cancer Metastatic
BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)
The BIOREN project aims are to characterize the genetic background of renal cell carcinomas and their immune environment, to try and identify biomarkers of response and to better understand the mechanisms of resistance to…
- Trial name
- BIOREN (NCT03628859)
- Testing
- Immunological and tumour characterization
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Centre Leon Berard
Renal Cell Cancer Metastatic, Hypertension
Sunitinib Treatment on Tissue Sodium Accumulation (TSS2)
Here, it is investigated how sunitinib, a tyrosine kinase-inhibitor targeting vascular endothelial growth factor receptors, might influence sodium homeostasis in the skin and if this is related to a well-described treatment…
- Conditions
- Renal Cell Cancer Metastatic, Hypertension, Sodium Imbalance
- Trial name
- NCT04368546
- Testing
- Sunitinib
- Where
- Germany
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Charite University, Berlin, Germany
Von Hippel-Lindau Syndrome
Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome
This open-label study will pilot the use of systemic sunitinib malate, a dual inhibitor of vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF), in five participants with Von Hippel-Lindau (VHL) to…
- Trial name
- VHL3 (NCT00673816)
- Testing
- Sunitinib Malate
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Eye Institute (NEI)
Gastrointestinal Stromal Tumors
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib.
With the development of KIT mutation and KIT tyrosine kinase inhibitor imatinib (GlivecTM, Novartis), survival of patients with advanced and/or metastatic gastrointestinal stromal tumor (GIST) has significantly improved.
- Trial name
- NCT03944304
- Testing
- Paclitaxel
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Asan Medical Center
Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal…
- Trial name
- NCT02231749
- Testing
- Nivolumab, Ipilimumab, Sunitinib
- Where
- 189 sites in United States, Argentina and 26 more
- Volunteers
- 1,096 people
- Sponsor
- Bristol-Myers Squibb